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The medical device industry is growing rapidly, with an estimated market over 
$300 billion globally. At the same time, cost containment pressures have 
translated into hospitals creating new decision-making processes and structures 
to control costs. In many hospitals, technology assessment committees (TACs), 
or value analysis committees (VACs), are a central feature of these cost 
containment strategies for medical devices. The question of what constitutes 
current decision-making processes and evidence needs of TACs/VACs, and more 
importantly, how evidence can best be communicated and leveraged, is central 
to the successful adoption of medical devices within hospitals. Our aim was to 
provide insight into evolving global hospital TAC/VAC requirements and to 
recommend a framework to deliver these requirements. A literature review was 
undertaken, in conjunction with case studies, to identify current TAC/VAC 
processes, member perspectives, decision-making factors (including evidence 
needs), and key challenges. Based on this evidence, a conceptual framework was 
developed which is composed of a systematic set of activities pertaining to 
“identifying”, “demonstrating” and “communicating” medical device value for 
enhanced product adoption. Central components of this framework, which have 
been tested in the field, include development of concise evidence-based payer 
dossiers and value messages, as well as sales force models that encompass both 
clinical and economic endpoints. Case studies of such tools, developed across 
diverse therapeutic areas (e.g., cardiovascular disease stenting, laparoscopic 
surgery), illustrate common and essential components. These include the need 
for indirect comparison methods when head-to-head comparative effectiveness 
data are lacking for appropriate medical device alternatives. In addition, data on 
outcomes relevant to the hospital from a cost-efficiency and quality 
improvement standpoint must be integrated. Testing of these tools has 
underscored the importance of customization of model parameters to hospital 
settings.  
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Quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) are 
summary health measures used in resource allocation decision making. 
However, the optimal choice of which summary measure to use in economic 
evaluations is unclear. On the basis of previously published literature, we 
attempt to clarify the use of summary health measures in cost-effectiveness 
analysis and recommend which summary measure to use for a given context. 
The selection of a summary health measure in cost-effectiveness analysis (CEA) 
depends to some extent on the philosophical background of the summary heath 
measures. Researchers may decide which measure to use based on the following 
selection criteria including but not limited to: 1) Purpose of research: DALYs are 
preferred for broader use in cost-effectiveness analysis, e.g., sectoral or 
generalized cost-effectiveness analysis. On the other hand, quality-adjusted life 
years (QALYs) are preferred for clinical decision making, evaluation of new 
clinical strategies, or program evaluation. 2) Norms: DALYs are preferably used 
in developing countries, whereas QALYs are the preferred outcome measure for 
conducting CEA in developed countries. 3) Availability of resources: The selection 
of a summary health measure is often driven by the availability of resources. 
Researchers in developing countries have limited resources in terms of funding 
to conduct CEAs using QALYs. On the other hand, disability weights representing 
population samples are easily accessible to researchers, which facilitate the use 
of DALYs as an outcome measure. The selection criteria for determining which 
summary health measure to use in CEA often overlap. The ultimate choice of 
summary measure should be based on the prioritization of goals and the 
availability of resources for the study.  
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Health Technology Assessment (HTA) is a multidisciplinary field of policy 
analysis that examines the clinical, social, ethical, and economic implications of 
the development, diffusion, and use of technology in health care, taking into 
consideration aspects such as efficiency, effectiveness, safety, cost, and cost-
effectiveness, among others. Although HTA should primarily consider the social, 
ethical, and legal impacts associated with technology, other basic attributes 
(efficacy, effectiveness, safety, and cost) end up taking precedence over the 
previous ones. But with the increasing emphasis on the engagement of patients 
as full partners in taking care of their own health, there is a need to establish 
effective means for their involvement in the decision-making process. The 
participation of society in HTA is crucial and needs to be implemented. In Brazil, 
community participation is one of the guidelines of the Brazilian Public Health 
System (SUS) present in the Federal Constitution of 1988. It’s also one of the 
principles outlined in Laws 8,080/1990 and 8,142/1990, that provide for 
community participation in the SUS. In 2011, Law 12,401 was enacted, 
officializing the participation of civil society in the process of incorporating 
technologies in the health system. However, it is necessary to analyze, discuss, 
and question how to actually introduce the patient and public preferences into 
HTA processes and in the process of incorporating new health technologies 
within the current Brazilian context (SUS perspective), given how important the 
broad suitability of new health technologies is. This is the aim of an ongoing 
study that will provide guidance to support HTA units in the Brazilian Ministry of 
Health and abroad in their decisions regarding patient participation.  
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OBJECTIVES: Creating interventions that engage/educate prostate cancer (PCa) 
patients and caregivers is an integral part of enhanced quality of care. A PCa 
management tool is intended to serve as a mechanism for more effective 
transitioning of patients through stages of care. Moreover, the development of a 
single-stop resource compendium is intended to objectively define quality care 
so that patients have a better understanding of their diagnosis and choices via a 
format that is not only easily understood but also enhances communication and 
trust with their health care providers (HCPs). METHODS: Part 1-Build a single 
source, web-based compendium of PCa resources for patients and caregivers, 
HCPs, and payers designed to engage and educate patients, facilitate 
understanding of treatment strategies, empower patients to work closely with 
their HCPs, and provide patients with resources and tools that enable enhanced 
quality decision-making. In addition the compendium will draw attention to the 
subset of patients, a disproportionate number of whom are from disparity or 
underserved populations, by identifying ways to address their unique needs. Part 
2-Develop a predictive model for PCa management that incorporates geographic 
variation in morbidity and mortality for PCa patients and provides customized 
pathway choices for treatment sequencing. RESULTS: (IN PROCESS) By 2020 
there will be a disproportionate increase in patient demand for cancer services, 
compared with the estimated 14% increase in oncology health care professionals 
available to support patients. In 2015 the Commission on Cancer (COC) will 
require providers to meet new standards to evaluate patients in distress placing 
additional stress on the current system. Under the Affordable Care Act (ACA), 
providers will be assuming more responsibility for patient behaviors and 
outcomes. In recognition of these challenges and timing of events we present the 
progress in the development of tools and interventions that can serve as an 
integral step in future patient-centered PCa care.  
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OBJECTIVES: To discuss the different methods of multi criteria decision analysis 
(MCDA) that could be used in health technology assessment (HTA) and their 
relative merits. The current practice of health technology appraisals is based on 
the incremental cost-effectiveness ratio (ICER). Even though other factors (e.g. 
severity, life saving, etc) are considered along with ICERs, there is concern that 
its approach may fail to capture other important sources of value. MCDA is 
aimed at supporting decision makers faced with evaluating alternatives taking 
into account multiple, and often conflictive, criteria in an explicit manner. 
METHODS: This paper begins with a critical review of state-of-the-art methods 
for incorporating multiple criteria in health technology assessment (HTA). A 
number of important questions are addressed to identify the most appropriate 
MCDA method that might be used to support decision making. For example, 
what criteria should be incorporated? Whose weights should be used and how to 
elicit them? How to incorporate uncertainty into the MCDA process? What 
should the ‘basic’ cost-effectiveness threshold be? This paper will discuss these 
questions, outline and assess methodological issues that would be raised by the 
use of MCDA in health technology assessment (HTA). RESULTS: MCDA does not 
just stop at simple weighting and scoring; more flexible approaches are available 
that appear to be more relevant to health technology appraisal and value based 
pricing (VBP). A potential MCDA approach for HTA is to calculate “weighted” 
QALYs from the QALY weights which reflect the broader value of the product’s 
benefits and compare against the updated “basic threshold” value. 
CONCLUSIONS: There are general practical issues that might arise from using 
this MCDA approach in the HTA process and further research needs to be 
performed to address the issues identified in order to ensure the success of this 
MCDA technique in the appraisal process.  
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OBJECTIVES: Ghana’s Community-based Health Planning and Service (CHPS) 
initiative to design a system for developing community based health care with 
full participation and support from community members. METHODOLOGY: The 
CHPS initiative scales up strategies developed and tested by a project of the 
Navrongo Health Research Centre in northern Ghana. Launched in 1994 as a 
three village pilot to develop strategies for mobilizing volunteerism, resources, 
and cultural institutions for supporting community-based primary health care, 
the project was expanded to a district-wide four celled trial in 1996. When 
evidence demonstrated that Navrongo strategies reduced childhood mortality, a 
replication project was launched in Nkwanta district to test and develop 
